Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-Current Assets (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Non-Current Assets for 14 consecutive years, with $5.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 33.76% year-over-year to $5.3 million, compared with a TTM value of $26.2 million through Dec 2025, up 8.39%, and an annual FY2025 reading of $5.3 million, down 33.76% over the prior year.
  • Non-Current Assets was $5.3 million for Q4 2025 at Karyopharm Therapeutics, down from $6.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $29.7 million in Q4 2021 and bottomed at $4.7 million in Q3 2024.
  • Average Non-Current Assets over 5 years is $10.0 million, with a median of $7.4 million recorded in 2023.
  • The sharpest move saw Non-Current Assets tumbled 78.99% in 2021, then soared 37.39% in 2025.
  • Year by year, Non-Current Assets stood at $29.7 million in 2021, then tumbled by 73.03% to $8.0 million in 2022, then dropped by 18.64% to $6.5 million in 2023, then grew by 22.08% to $8.0 million in 2024, then plummeted by 33.76% to $5.3 million in 2025.
  • Business Quant data shows Non-Current Assets for KPTI at $5.3 million in Q4 2025, $6.5 million in Q3 2025, and $7.0 million in Q2 2025.